Long Road Ahead for Stem Cell Initiative
Proposal to Finance Research Qualifies for State Ballot
By Carl T. Hall,
San Francisco Chronicle
| 06. 04. 2004
A $3 billion state proposition to promote controversial stem cell
research in California qualified Thursday for the November ballot,
opening what promises to be a bruising campaign that pits moral critics
of the research against family members of people with incurable
diseases.
The ballot initiative represents an
ambitious attempt to circumvent President Bush's stem cell policy,
which severely restricts research in the field. Even so, some promoters
of the research say state funding would set a dangerous precedent in
departing from the system of federally financed biomedical research.
Supporters
of the "California Stem Cell Research and Cures Initiative" said they
turned in about 1.1 million signatures to California Secretary of State
Kevin Shelley, almost twice the minimum needed to put the measure
before state voters in the presidential election on Nov. 2.
The
measure, which requires a simple majority to pass, would authorize an
average $295 million a year in state-backed bonds to be issued over 10
years. Although the bonds would be guaranteed by tax revenue, no
payments would be due for the first five years.
The
ballot measure...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...